Google faces setback as EU court adviser backs antitrust regulators
By Foo Yun Chee
BRUSSELS (Reuters) -Alphabet's Google faced a potential setback on Thursday as an adviser to Europe's highest court sided with EU antitrust regulators in the company's fight against a record 4.34 billion euro ($4.98 billion) fine levied seven years ago.
The European Commission in its 2018 decision said Google had used its Android mobile operating system to block rivals. A lower tribunal endorsed the EU finding in 2022 but trimmed the fine to 4.1 billion euros, prompting Google to appeal to Europe's top court.
Advocate-General at the Luxembourg-based Court of Justice of the European Union (CJEU) Juliane Kokott, in her non-binding opinion, advised the court to dismiss Google's appeal and confirm the reduced fine set by the lower tribunal.
"The legal arguments put forward by Google are ineffective," she said.
Kokott dismissed Google's argument that regulators should compare Google with a rival in assessing the situation.
"It is not realistic, in the present case, to compare the situation of Google with that of a hypothetical as-efficient competitor. Google held a dominant position in several markets of the Android-ecosystem and thus benefited from network effects that enabled it to ensure that users used Google Search," she said.
Judges, who usually follow four out of five such non-binding opinions, will rule in the coming months.
"Android has created more choice for everyone and supports thousands of successful businesses in Europe and around the world," a Google spokesperson said on Thursday.
"We are disappointed with the Opinion which, if it were followed by the Court, would discourage investment in open platforms and harm Android users, partners and app developers."
Regulators said Google's illegal practices dated back to 2011, as it required manufacturers to pre-install Google Search and its Chrome browser together with its Google Play app store on their Android devices. It paid them to pre-install only Google Search and blocked them from using rival Android systems.
Google's Android system, which it lets device makers use for free, runs about 73% of the world's smartphones, according to Statcounter.
The world's most popular internet search engine has racked up a total of 8.25 billion euros in fines linked to three investigations stretching back more than a decade, while other probes are ongoing.
The case is C-738/22 P Google and Alphabet v Commission.
($1 = 0.8726 euros)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox Sports
an hour ago
- Fox Sports
Top 10 Richest Team Purchases: Lakers Sell for Record $10 billion
The family-owned Los Angeles Lakers are about to be sold at a valuation of $10 billion, smashing the previous record for the purchase price for a team sport. The cross-country rival Boston Celtics went for $6.1 billion just three months ago. With team values soaring, there have been a number of notable franchise transactions in recent years: Los Angeles Lakers The Lakers have been in the Buss family since 1979, but Jeanie Buss has agreed to sell the NBA's most valuable franchise to L.A. Dodgers owner Mark Walter. Boston Celtics The Celtics, who won their record 18th NBA championship last year, went for $6.1 billion in March to private equity mogul Bill Chisholm. Washington Commanders Josh Harris, who with David Blitzer owns the NBA's Philadelphia 76ers and NHL's New Jersey Devils, added to his sports portfolio in 2023 by purchasing the Commanders for a then-record $6.05 billion. Chelsea The English Premier League team went to a consortium fronted by Dodgers part owner Todd Boehly that also includes Walter in 2022 for $3.2 billion. Another $2.2 billion was pledged for infrastructure and associated teams. Denver Broncos The Walton-Penner ownership group led by Walmart heir Rob Walton bought the NFL team in 2022 for $4.65 billion. Phoenix Suns Mortgage executive Mat Ishbia purchased the team for a then-NBA record $4 billion in 2022. Dallas Mavericks Mark Cuban sold the NBA franchise in 2023 for $3.5 billion to the Adelson family, which owns the Las Vegas Sands casino company. Charlotte Hornets Michael Jordan agreed to sell his majority share in the NBA's Hornets in 2023 for $3 billion to Rick Schnall and Gabe Plotkin. Schnall had a minority ownership in the NBA's Atlanta Hawks and Plotkin in the Hornets. New York Mets Steve Cohen completed one of the richest purchases of an MLB team in recent memory, acquiring the Mets for $2.4 billion in 2020. It marked a monumental shift for the Queens-based New York franchise as they had been under the control of the disgraced Wilpon family. Brooklyn Nets Joe Tsai purchased the Brooklyn Nets for approximately $2.5 billion in 2019. He paid a total of $3 billion, but that included acquiring the Barclays Center in the deal. He bought the team from previous owner Mikhail Prokorov. The Associated Press contributed to this report. Want great stories delivered right to your inbox? Create or log in to your FOX Sports account and follow leagues, teams and players to receive a personalized newsletter daily! recommended Get more from National Basketball Association Follow your favorites to get information about games, news and more
Yahoo
an hour ago
- Yahoo
HER2-low Cancers Market Set to Register Immense Growth at a CAGR of 9.4% During the Study Period (2020-2034)
The future of the HER2-low cancer treatment market is poised for significant transformation, driven by the approval of ENHERTU and the advancement of other innovative antibody-drug conjugates (ADCs) like DATROWAY, TRODELVY, ifinatamab deruxtecan, BB-1701, and Disitamab vedotin. These ADCs are designed to target HER2-low-expressing cancer cells, with major development ongoing in Breast Cancer. LAS VEGAS, June 19, 2025 /PRNewswire/ -- DelveInsight's HER2-low Cancers Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging HER2-low cancer therapies, market share of individual therapies, and current and forecasted HER2-low cancers market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the HER2-low Cancers Market Report HER2-low cancer refers to tumors with low HER2 protein expression that do not meet the criteria for HER2-positive classification. The prevalence of HER2-low expression varies across cancers, occurring in approximately 63% of breast cancers, 42% of biliary tract cancers, 38% of urothelial carcinomas, and 35% of gastric cancers. As per DelveInsight's analysis, the total market size of HER2-low cancers in the 7MM was USD 3.2 billion in 2024 and is projected to grow during the forecast period (2025-2034), driven by ENHERTU's usage and strong uptake in this cancer type. Of the target indications, breast cancer and gastric cancer are anticipated to generate the most revenue by 2034 due to the highest level of clinical development and authorization of HER2-low cancer therapies. Among all therapies, ENHERTU is expected to capture the highest market share, due to its proven clinical efficacy, strong safety, and first-mover advantage in treating HER2-low cancers. Based on Delveinsight's assessment in 2024, the 7MM had approximately 360,000 target pool cases of HER2-low cancers. These cases are projected to increase during the forecast period (2025–2034) due to recent clinical advances recognizing HER2-low as a distinct category, thereby expanding the treatable patient population There are no HER2-targeting therapies currently in the pipeline for first-line treatment; all available options are focused on the relapsed or refractory setting. The HER2-low breast cancer pipeline is becoming increasingly competitive, as ENHERTU has dramatically shifted market dynamics. Its approval for HER2-low breast cancer has significantly transformed the market trajectory, leading to a doubling of overall sales in 2023. Leading HER2-low cancer companies, such as AstraZeneca, Daiichi Sankyo, RemeGen, Pfizer (Seagen), Gilead Sciences, Merck, Bliss Biopharmaceutical (Hangzhou), Zymeworks, Jazz Pharmaceuticals, ALX Oncology, Dragonfly Therapeutics, Mersana Therapeutics, and others, are developing novel HER2-low cancer therapies that can be available in the HER2-low cancer market in the coming years. Some of the key HER2-low cancer therapies in the pipeline include DATROWAY (datopotamab deruxtecan/Dato-DXd), AIDIXI (disitamab vedotin), TRODELVY (sacituzumab govitecan), Ifinatamab deruxtecan (I-DXd)/MK-2400, BB-1701, ZIIHERA (zanidatamab), DF1001, Emiltatug ledadotin (XMT-1660), and others. Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report HER2-low Cancers Market Dynamics The HER2-low cancer market has recently garnered significant attention, primarily due to the advancements in targeted therapies for cancers with low expression of the HER2 protein. While HER2-positive cancers, such as breast and gastric cancers, have long been the focus of targeted treatments like trastuzumab (HERCEPTIN), HER2-low cancers represent a distinct subset that requires different therapeutic strategies. These cancers exhibit a lower level of HER2 expression, making them more challenging to treat with traditional HER2-targeted therapies. However, recent breakthroughs in ADCs and novel monoclonal antibodies are starting to offer new avenues for patients with this subgroup. As researchers continue to explore HER2-low cancers, one of the key dynamics driving the market is the recognition that these tumors can benefit from a broader range of treatments. In particular, ADCs are showing promise as they allow for more precise delivery of chemotherapy agents directly to tumor cells. This approach offers hope for patients whose cancers were previously thought to be less amenable to targeted therapies. The approval of drugs like ENHERTU for HER2-low breast cancer has created a significant shift in the oncology treatment landscape, leading to a surge of interest from pharmaceutical companies developing similar therapies. The growing understanding of HER2-low cancers has also influenced diagnostic practices, with an emphasis on accurate biomarker testing. Companies are now focusing on developing more sensitive and specific assays to detect low levels of HER2 expression, ensuring that patients are correctly identified for targeted treatment options. This has led to the rise of precision medicine in oncology, where treatments are tailored not only to the type of cancer but also to the molecular characteristics of the tumor. The better the diagnostics, the more likely it is that patients will receive appropriate therapies, boosting market potential. Additionally, market dynamics are shaped by the competitive landscape, with several big pharmaceutical companies investing heavily in the development of new agents for HER2-low cancers. The approval of HER2-targeted treatments for low-expressing cancers is expected to trigger a surge in demand, especially in indications such as breast and gastric cancers. However, challenges remain, including the cost of these novel therapies, their accessibility in different healthcare settings, and the need for continued clinical validation. As these therapies advance through the pipeline, the future market for HER2-low cancer treatments looks promising, but it will require a combination of scientific innovation, regulatory support, and healthcare infrastructure to realize its full potential. HER2-low Cancers Treatment Market HER2-low cancers, which are marked by low levels of the HER2 protein, pose distinct treatment challenges. Recent research has focused on targeted therapies for such cancers, especially breast cancers. Treatment options for HER2-low cancers, including gastric, endometrial, and other cancers, are evolving as research continues to explore the role of HER2 in these diseases. Traditional therapies, such as monoclonal antibodies and small molecular Tyrosine Kinase Inhibitors (TKIs), have shown limited effectiveness in breast cancers with HER2-low expression. For years, HER2-low breast cancer has been treated similarly to HER2-negative breast cancer, including HR+/HER2− and TNBC cases. For gastric cancer, particularly adenocarcinoma of the stomach and gastroesophageal junction, recent research has highlighted the potential of ENHERTU, an antibody-drug conjugate. ENHERTU has shown promising results in patients with HER2-low expression (IHC 1+ or 2+/ISH−). In January 2025, ENHERTU was approved by the US FDA for treating adult patients with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow (IHC 0 with membrane staining) breast cancer, who have progressed on one or more endocrine therapies in the metastatic setting, based on an FDA-approved test. For HR-negative/HER2-low breast cancer, treatment usually begins with first-line chemotherapy, potentially combined with immunotherapy for PD-L1-positive patients, followed by sequential chemotherapy treatments. For HR-positive breast cancer, due to its progression-free survival advantage over chemotherapy, PARP inhibitors (PARPi) are considered for patients with a germline BRCA mutation. Learn more about the FDA-approved HER2-low cancer therapies @ HER2-low Cancer Treatment Drugs HER2-low Cancers Pipeline Therapies and Key Companies Currently, the clinical development landscape includes late and mid-stage assets. Consequently, our forecast considers the potential impact of Pfizer's Disitamab vedotin, Immutep's Eftilagimod alpha (IMP321), AstraZeneca and Daiichi Sankyo's DATROWAY, Gilead Sciences' TRODELVY, Duality Biologics and BioNTech's DB-1303/BNT323, Daiichi Sankyo and Merck's Ifinatamab deruxtecan, Bliss Biopharmaceutical's BB-1701, and Dragonfly Therapeutics' DF1001. Dato-DXd is an experimental TROP2-targeted ADC, developed using Daiichi Sankyo's proprietary DXd ADC Technology. It is one of six DXd ADCs in their oncology pipeline and a key program in AstraZeneca's ADC scientific platform. In collaboration with Sapporo Medical University, Dato-DXd is designed with topoisomerase I inhibitor payloads linked via tetrapeptide-based cleavable linkers. The drug is currently in Phase III trials for inoperable or metastatic HR-positive, HER2-low or negative breast cancer (IHC 0, IHC 1+, or IHC 2+/ISH-) that has previously been treated with endocrine therapy and at least one systemic therapy. AstraZeneca expects Phase I results from the TROPION-PanTumor01 trial (NCT03401385) to be available in the latter half of 2025, as reported in their 2024 clinical trial appendix. In February 2025, Daiichi Sankyo presented data from the Phase III TROPION-Breast01 DATROWAY trial for HR+/HER2-low breast cancer at the ESMO Virtual Meeting. While overall survival did not reach statistical significance, Dato-DXd showed a manageable safety profile and continued to favor the investigator's choice of chemotherapy on secondary efficacy endpoints. TRODELVY is a first-in-class TROP-2-targeting ADC designed with a proprietary hydrolyzable linker and SN-38, a topoisomerase I inhibitor payload. This combination delivers potent activity to TROP-2-expressing cells and the surrounding microenvironment. It is currently undergoing Phase III trials for HR-positive/HER-negative (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH–]) inoperable, locally advanced, or metastatic breast cancer after endocrine therapy. Its patent is set to expire in the US by 2028 and in Europe by 2029. BNT323/DB-1303 is a third-generation ADC targeting HER2, built on DualityBio's proprietary Duality Immune Toxin Antibody Conjugates (DITAC) platform. This candidate has shown antitumor activity in HER2-positive and HER2-low tumor models, as well as in multiple solid tumors, including breast, gastric, endometrial, biliary tract cancers, and other advanced solid tumors. BNT323/DB-1303 is currently being evaluated in a Phase I/II study (NCT05150691) for advanced/metastatic solid tumors and in a pivotal Phase III study (NCT06018337) for HR-positive and HER2-low, metastatic breast cancer that has progressed on hormone and/or CDK4/6 therapy. The anticipated launch of these emerging therapies are poised to transform the HER2-low cancers market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the HER2-low cancers market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about HER2-low cancer drug clinical trials, visit @ HER2-low Cancer Drugs Recent Developments in the HER2-low Cancer Market In January 2025, the US FDA approved ENHERTU for adults with unresectable or metastatic HR+, HER2-low or HER2-ultralow breast cancer, based on DESTINY-Breast06 Phase III results following progression on one or more endocrine therapies. In January 2025, the US FDA granted FTD to emiltatug ledadotin, B7-H4 ADC, for advanced or metastatic HER2-low or HER2-negative breast cancer, including triple-negative cases previously treated with a topoisomerase-1 inhibitor ADC, based on promising results from a Phase I trial. As per BioNTech's Q4 2024 annual presentation, published in March 2025, the company plans to prioritize the advancement of DB-1303 for BLA submission in 2025 as a second-line or subsequent therapy in HER2-expressing advanced endometrial cancer. According to Pfizer's presentation, the launch of disitamab vedotin for second-line HER2+/low metastatic urothelial carcinoma is expected in 2026. HER2-low Cancers Overview HER2 is a transmembrane tyrosine kinase receptor encoded by the ERBB2 gene, playing a crucial role in cell growth, differentiation, and survival. It is part of the epidermal growth factor receptor family and is typically analyzed using molecular techniques. HER2 protein overexpression is assessed through immunohistochemistry (IHC), while gene amplification is determined using fluorescence in situ hybridization (FISH). A HER2-low status is defined as an IHC score of 1+ or 2+, with no gene amplification detected by FISH. HER2/neu primarily activates the MAPK and PI3K pathways, contributing to malignant transformation when overexpressed or amplified. This receptor is found in several cancers, including breast, colorectal, ovarian, endometrial, bladder, gastric, and biliary tract cancers, with breast cancer being the most prevalent. HER2-low Cancers Epidemiology Segmentation In the 7MM, in 2024, among all the HER2-low cancer indications, breast cancer accounted for the highest number of incident cases, while ovarian cancer occupied the bottom of the ladder. The HER2-low cancers market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Targeted Patient Pool of Selected Indications for HER2-low Cancers Treatment Eligible Pool of Selected Indications for HER2-low Cancers Total Incident Cases of HER2-low Breast Cancers Age-specific Cases of HER2-low Breast Cancers Stage-specific Cases of HER2-low Breast Cancers HER2-low Cancers Report Metrics Details Study Period 2020–2034 HER2-low Cancers Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] HER2-low Cancer Market CAGR 9.4 % HER2-low Cancer Market Size in 2024 USD 3.2 billion Key HER2-low Cancer Companies AstraZeneca, Daiichi Sankyo, RemeGen, Pfizer (Seagen), Gilead Sciences, Merck, Bliss Biopharmaceutical (Hangzhou), Zymeworks, Jazz Pharmaceuticals, ALX Oncology, Dragonfly Therapeutics, Mersana Therapeutics, and others Key HER2-low Cancer Therapies ENHERTU, DATROWAY (datopotamab deruxtecan/Dato-DXd), AIDIXI (disitamab vedotin), TRODELVY (sacituzumab govitecan), Ifinatamab deruxtecan (I-DXd)/MK-2400, BB-1701, ZIIHERA (zanidatamab), DF1001, Emiltatug ledadotin (XMT-1660), and others Scope of the HER2-low Cancers Market Report HER2-low Cancers Therapeutic Assessment: HER2-low Cancers current marketed and emerging therapies HER2-low Cancers Market Dynamics: Conjoint analysis of approved and emerging HER2-low Cancers Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Cost assumptions, HER2-low Cancers Market Access and Reimbursement Discover more about HER2-low cancer drugs in development @ HER2-low Cancers Clinical Trials Table of Contents 1 KEY INSIGHTS 2 REPORT INTRODUCTION 3 EXECUTIVE SUMMARY 4 KEY EVENTS 5 EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY 6 HER2-LOW CANCERS MARKET OVERVIEW AT A GLANCE 6.1 MARKET SHARE (%) DISTRIBUTION BY THERAPIES OF HER2-LOW CANCERS IN 2024 IN THE 7MM 6.2 MARKET SHARE (%) DISTRIBUTION BY THERAPIES OF HER2-LOW CANCERS IN 2034 IN THE 7MM 6.3 MARKET SHARE (%) DISTRIBUTION BY INDICATIONS IN 2024 IN THE 7MM 6.4 MARKET SHARE (%) DISTRIBUTION BY INDICATIONS IN 2034 IN THE 7MM 7 DISEASE BACKGROUND AND OVERVIEW 7.1 INTRODUCTION 7.2 SYMPTOMS 7.3 RISK FACTORS 7.4 PATHOPHYSIOLOGY OF HER2-LOW CANCERS 7.5 PROGNOSIS 7.6 DIAGNOSIS 7.7 TREATMENT 7.8 GUIDELINES 7.8.1 Diagnostic Guidelines and Recommendations for HER2-low Cancers 7.8.1.1 ASCO Diagnostic Recommendations for HER2 Testing 7.8.1.2 The ASCO-College of American Pathologists (CAP) Recommendations for HER2 Testing 7.8.1.3 ESCO Guidelines for HER2-low Cancers 7.8.1.4 Interpretation by the ASCO/CAP 2018 Guidelines and by the 2023 ESMO Consensus on HER2-low Breast Cancer Regarding Each Pattern of HER2 Staining 7.8.1.5 Pan-Asian Adapted ESMO Guidelines for HER2-low Cancers 7.8.1.6 Japanese Breast Cancer Society Clinical Practice Guidelines for Pathological Diagnosis of Breast Cancer, 2022 Edition 7.8.2 Treatment Guidelines and Recommendations for HER2-low Cancers 7.8.2.1 ESMO Guidelines for HER2-low Cancers 7.8.2.2 Pan-Asian Adapted ESMO Guidelines for HER2-low Cancers 8 EPIDEMIOLOGY AND PATIENT POPULATION 8.1 KEY FINDINGS 8.2 ASSUMPTION AND RATIONALE OF HER2-LOW CANCERS: THE 7MM 8.3 TOTAL TARGETED PATIENT POOL OF SELECTED INDICATIONS FOR HER2-LOW CANCERS IN THE 7MM 8.4 TREATMENT ELIGIBLE POOL OF SELECTED INDICATIONS FOR HER2-LOW CANCERS IN THE 7MM 8.5 THE UNITED STATES 8.5.1 Total Incident Cases of HER2-low Breast Cancers in the United States 8.5.2 Age-specific Cases of HER2-low Breast Cancers in the United States 8.5.3 Stage-specific Cases of HER2-low Breast Cancers in the United States 8.6 EU4 AND THE UK 8.6.1 Total Incident Cases of HER2-low Breast Cancers in EU4 and the UK 8.6.2 Age-specific Cases of HER2-low Breast Cancers in EU4 and the UK 8.6.3 Stage-specific Cases of HER2-low Breast Cancers in EU4 and the UK 8.7 JAPAN 8.7.1 Total Incident Cases of HER2-low Breast Cancers in Japan (2020-2034) 8.7.2 Age specific Cases of HER2-low Breast Cancers in Japan 8.7.3 Stage-specific Cases of HER2-low Breast Cancers in Japan 9 PATIENT JOURNEY 10 MARKETED DRUG 10.1 KEY COMPETITOR 10.2 ENHERTU (TRASTUZUMAB DERUXTECAN): DAIICHI SANKYO AND ASTRAZENECA 10.2.1 Product Description 10.2.2 Regulatory Milestones 10.2.3 Other Developmental Activities 10.2.4 Clinical Development 10.2.4.1 Clinical Trial Information 10.2.5 Safety and Efficacy 11 EMERGING THERAPIES 11.1 KEY CROSS COMPETITION 11.2 DATROWAY (DATOPOTAMAB DERUXTECAN/DATO-DXD): ASTRAZENECA AND DAIICHI SANKYO 11.2.1 Product Description 11.2.2 Other Developmental Activities 11.2.3 Clinical Development 11.2.3.1 Clinical Trials Information 11.2.4 Safety and Efficacy 11.2.5 Analyst Views 11.3 TRODELVY (SACITUZUMAB GOVITECAN): GILEAD SCIENCES 11.3.1 Product Description 11.3.2 Other Developmental Activities 11.3.3 Clinical Development 11.3.3.1 Clinical Trials Information 11.3.4 Safety and Efficacy 11.3.5 Analyst Views 11.4 DB-1303/BNT323 (TRASTUZUMAB PAMIRTECAN): DUALITY BIOLOGICS AND BIONTECH 11.4.1 Product Description 11.4.2 Other Developmental Activities 11.4.3 Clinical Development 11.4.3.1 Clinical Trials Information 11.4.4 Safety and Efficacy 11.4.5 Analyst Views 11.5 AIDIXI (DISITAMAB VEDOTIN): REMEGEN AND PFIZER (SEAGEN) 11.5.1 Product Description 11.5.2 Other Developmental Activities 11.5.3 Clinical Development 11.5.4 Safety and Efficacy 11.5.5 Analyst Views 11.6 EFTILAGIMOD ALPHA (IMP321): IMMUTEP 11.6.1 Product Description 11.6.2 Other Developmental Activities 11.6.3 Clinical Development 11.6.3.1 Clinical Trials Information 11.6.4 Safety and Efficacy 11.6.5 Analyst Views 11.7 IFINATAMAB DERUXTECAN (I-DXD)/MK-2400: DAIICHI SANKYO AND MERCK 11.7.1 Product Description 11.7.2 Other Developmental Activities 11.7.3 Clinical Development 11.7.3.1 Clinical Trials Information 11.7.4 Analyst Views 11.8 BB-1701: BLISS BIOPHARMACEUTICAL (HANGZHOU) 11.8.1 Product Description 11.8.2 Other Developmental Activities 11.8.3 Clinical Development 11.8.3.1 Clinical Trials Information 11.8.4 Safety and Efficacy 11.8.5 Analyst Views 11.9 DF1001: DRAGONFLY THERAPEUTICS 11.9.1 Product Description 11.9.2 Other Developmental Activities 11.9.3 Clinical Development 11.9.3.1 Clinical Trials Information 11.9.4 Safety and Efficacy 11.9.5 Analyst Views 11.1 ZIIHERA (ZANIDATAMAB): ZYMEWORKS/JAZZ PHARMACEUTICALS/ALX ONCOLOGY 11.10.1 Product Description 11.10.2 Other Developmental Activities 11.10.3 Clinical Development 11.10.4 Safety and Efficacy 11.10.5 Analyst Views 11.11 HF158K1/HF-K1: HIGHFIELD BIOPHARMACEUTICALS 11.11.1 Product Description 11.11.2 Other Developmental Activities 11.11.3 Clinical Development 11.11.3.1 Clinical Trials Information 11.11.4 Safety and Efficacy 11.11.5 Analyst Views 11.12 EMILTATUG LEDADOTIN (XMT-1660): MERSANA THERAPEUTICS 11.12.1 Product Description 11.12.2 Other Developmental Activities 11.12.3 Clinical Development 11.12.3.1 Clinical Trials Information 11.12.4 Safety and Efficacy 11.12.5 Analyst Views 12 HER2-LOW CANCERS: SEVEN MAJOR MARKET ANALYSIS 12.1 KEY FINDINGS 12.2 MARKET OUTLOOK 12.3 CONJOINT ANALYSIS 12.4 KEY MARKET FORECAST ASSUMPTIONS 12.4.1 Cost Assumptions 12.4.2 Pricing Trends 12.4.3 Analogue Assessment 12.4.4 Launch Year and Therapy Uptakes 12.5 TOTAL MARKET SIZE OF HER2-LOW CANCERS BY COUNTRY IN THE 7MM 12.6 TOTAL MARKET SIZE OF HER2-LOW CANCERS BY INDICATIONS IN THE 7MM 12.7 MARKET SIZE OF HER2-LOW CANCERS BY THERAPIES IN 7MM 12.8 UNITED STATES MARKET SIZE 12.8.1 Total Market Size of HER2-low Cancers in the United States 12.8.2 Market Size of HER2-low Cancers by Therapies in the United States 12.9 EU4 AND THE UK MARKET SIZE 12.9.1 Total Market Size of HER2-low Cancers in EU4 and the UK 12.9.2 Market Size of HER2-low Cancers by Therapies in EU4 and the UK 12.1 JAPAN 12.10.1 Total Market Size of HER2-low Cancers in Japan 12.10.2 Market Size of HER2-low Cancers by Therapies in Japan 13 UNMET NEEDS 14 SWOT ANALYSIS 15 KOL VIEWS 16 MARKET ACCESS AND REIMBURSEMENT 16.1 UNITED STATES 16.1.1 Centre for Medicare and Medicaid Services (CMS) 16.2 EU4 AND THE UK 16.2.1 Germany 16.2.2 France 16.2.3 Italy 16.2.4 Spain 16.2.5 United Kingdom 16.3 JAPAN 16.3.1 MHLW 16.4 MARKET ACCESS AND REIMBURSEMENT OF HER2-LOW CANCERS 17 APPENDIX 17.1 BIBLIOGRAPHY 17.2 REPORT METHODOLOGY 18 DELVEINSIGHT CAPABILITIES 19 DISCLAIMER 20 ABOUT DELVEINSIGHT Related Reports HER2+ Market HER2+ Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of HER2+, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HER2+ companies, including Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven Therapeutics, Roche, among others. Metastatic HER2-Positive Breast Cancer Market Metastatic HER2-Positive Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic HER2-positive breast cancer companies, including Byondis, Roche, Ambrx, Zymeworks, Jazz Pharmaceuticals, Pfizer, among others. Metastatic HR+/HER2-negativeBreast Cancer Market Metastatic HR+/HER2− Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic HR+/HER2-negative breast cancer companies including Merck, Arvinas, Olema Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, among others. Triple Negative Breast Cancer Market Triple Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key TNBC companies including AstraZeneca, Daiichi Sankyo, OBI Pharma, Astellas Pharma, Pfizer, Galera Therapeutics, BioNTech, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hill
2 hours ago
- The Hill
Trump extends TikTok sale deadline
The Big Story President Trump extended the deadline for TikTok's parent company to divest the popular video sharing app by 90 days. © Manuel Balce Ceneta, Associated Press The order punts the deadline for China-based ByteDance to Sept. 17. The most recent deadline was Thursday. 'I've just signed the Executive Order extending the Deadline for the TikTok closing for 90 days (September 17, 2025). Thank you for your attention to this matter!' Trump wrote in a post on Truth Social, attaching a screenshot of the order. The order instructs the Department of Justice not to enforce the law or impose penalties related to it. 'We are grateful for President Trump's leadership and support in ensuring that TikTok continues to be available for more than 170 million American users and 7.5 million U.S. businesses that rely on the platform as we continue to work with Vice President Vance's Office,' TikTok said in a statement following Thursday's order. White House press secretary Karoline Leavitt confirmed earlier this week Trump planned to sign another extension, telling reporters the president 'does not want TikTok to go dark.' 'This extension will last 90 days, which the Administration will spend working to ensure this deal is closed so that the American people can continue to use TikTok with the assurance that their data is safe and secure,' Leavitt said in a statement Tuesday. When asked Monday whether he would give the popular video-sharing platform another extension, the president told reporters aboard Air Force One, 'Probably, yeah.' 'Probably have to get China['s] approval, but I think we'll get it,' Trump said as he traveled back from the Group of Seven summit in Canada. 'I think President Xi [Jinping] will ultimately approve it.' The order marks the third extension from Trump since he took office in January. Read more in a full report at Welcome to The Hill's Technology newsletter, we're Miranda Nazzaro and — tracking the latest moves from Capitol Hill to Silicon Valley. Did someone forward you this newsletter? Subscribe here. Essential Reads How policy will be impacting the tech sector now and in the future: Misleading information on climate science delaying action: Report Misleading information about the nature of climate change is further complicating and delaying action to fight the environmental issue, according to a new research report. A sprawling report, released this month from the International Panel on the Information Environment (IPIE), found 'powerful actors' like governments, political parties and corporations are often behind the intentional spreading of inaccurate or … Texas Democrats ask Tesla to delay robotaxi rollout A group of Democratic lawmakers in Texas urged Tesla to delay the rollout of its robotaxis in Austin, as the driverless cars prepare to hit the streets this weekend. In a letter to Tesla's director of field quality, Eddie Gates, seven lawmakers asked the electric vehicle maker to push back its launch until September, when a new Texas law is set to take effect. The law, which revises earlier state guidelines for autonomous … SpaceX rocket explodes during test A SpaceX rocket exploded late Wednesday during a static fire test, which the company attributed to 'a major anomaly.' 'On Wednesday, June 18 at approximately 11 p.m. CT, the Starship preparing for the tenth flight test experienced a major anomaly while on a test stand at Starbase,' the aerospace company, owned by tech billionaire Elon Musk, wrote early Thursday on the social platform X. 'A safety clear area around … Honda says it successfully launched and landed reusable rocket Honda successfully launched and landed its experimental reusable rocket at its facility in Japan, the company said in a surprise announcement Tuesday. The rocket reached an altitude of 271.4 meters, or roughly 890 feet, and landed within 37 centimeters, or roughly 15 inches, of the target touchdown point, the company said. The duration of the flight was 56.6 seconds. 'The test was completed successfully, the first time Honda … The Refresh News we've flagged from the intersection of tech and other topics: Crypto Corner Trump calls on House to pass 'clean' stablecoin bill © Evan Vucci, Associated Press Welcome to Crypto Corner, a daily feature focused on digital currency and its outlook in Washington. President Trump is urging House lawmakers to pass stablecoin legislation that cleared the Senate earlier this week without any major additions — a demand that may clash with hopes of tying two key crypto bills together. 'The Senate just passed an incredible Bill that is going to make America the UNDISPUTED Leader in Digital Assets — Nobody will do it better, it is pure GENIUS!' Trump wrote in a post on Truth Social of the GENIUS Act. 'Digital Assets are the future, and our Nation is going to own it,' he continued. 'We are talking about MASSIVE Investment, and Big Innovation. The House will hopefully move LIGHTNING FAST, and pass a 'clean' GENIUS Act.' The Senate voted 68-30 Tuesday to pass the GENIUS Act Tuesday, with 18 Democrats joining most Republicans to get the stablecoin bill across the finish line. It marked a milestone moment for the crypto industry as the first major digital asset legislation to clear the chamber. 'Get it to my desk, ASAP — NO DELAYS, NO ADD ONS,' Trump added. 'This is American Brilliance at its best, and we are going to show the World how to WIN with Digital Assets like never before!' After embracing the industry on the campaign trail, Trump has made crypto legislation a priority for his administration, pushing to pass two crypto bills before Congress leaves for its August recess. In addition to the stablecoin bill, the White House and GOP lawmakers are trying to pass legislation that would divvy up oversight of the rest of the digital asset market between two financial regulators. While Trump pushes lawmakers to get a 'clean' GENIUS Act to his desk as fast as possible, some in the industry and Congress have voiced support for tying the two crypto bills together to ensure they don't lose momentum before getting to market structure. However, others are pushing to take the win on stablecoin legislation and tackle market structure legislation afterward. In Other News Branch out with other reads on The Hill: Vance briefly booted from Bluesky after joining platform Vice President Vance was briefly suspended from the social media network Bluesky shortly after joining the platform Wednesday, but was quickly reinstated online. Publishing his first post on Bluesky on Wednesday evening, Vance wrote, 'Hello Bluesky, I've been told this app has become the place to go for common sense political discussion and analysis. So I'm thrilled to be here to engage with all of you.' … What Others are Reading Two key stories on The Hill right now: Fannie, Freddie overseer wages online war against Fed chief The overseer of Fannie Mae and Freddie Mac is waging an online battle to force out Federal Reserve Chair Jerome Powell. Over the span of 24 hours, … Read more Leavitt: Trump to decide on Iran action in next 2 weeks President Trump is expected to make a decision about whether to take direct action against Iran in the next two weeks, he said Thursday in a message … Read more What Others are Reading Opinion related to tech submitted to The Hill: You're all caught up. See you tomorrow! Thank you for signing up! Subscribe to more newsletters here
